Skip to main content
BASKHANBIOPharma Inc. logo

BASKHANBIOPharma Inc. — Investor Relations & Filings

Ticker · 354390 ISIN · KR7354390007 KO Manufacturing
Open in API
Filings indexed 71 across all filing types
Latest filing 2025-03-31 Major Shareholding Noti…
Country KR South Korea
Listing KO 354390

About BASKHANBIOPharma Inc.

http://www.baskhanbio.com/

BASKHANBIOPharma Inc. is a pharmaceutical company focused on pain management and improving patient quality of life. The company engages in the manufacture, sale, and distribution of a diverse product portfolio. Its core offerings include prescription drugs, over-the-counter (OTC) medicines, and medical devices, with a particular emphasis on products used before, during, and after surgical procedures. In addition to its primary pharmaceutical and medical device operations, the company's business areas also encompass health functional foods and cosmetics.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details changes in share ownership by major shareholders and special related parties, including reasons for changes such as stock option expirations and director resignations. This type of filing is specifically categorized as a Major Shareholding Notification.
2025-03-31 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details the changes in the board of directors, specifically regarding outside directors, which falls under the category of Board/Management Information (MANG).
2025-03-27 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회 결과' (Annual General Meeting Results) and details the outcomes of various agenda items such as financial statement approval, director/auditor appointments, and remuneration limits. This aligns perfectly with the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-03-26 Korean
사업보고서 (2024.12)
Interim / Quarterly Report Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'Baskan Bio Pharm' (주식회사 바스칸바이오제약) for the fiscal years 2023 and 2024. It includes the independent auditor's opinion, financial statements (Statement of Financial Position, Comprehensive Income Statement, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. This constitutes a comprehensive annual financial report for a period, which falls under the 'Interim / Quarterly Report' (IR) category in the provided schema, as it contains the full set of audited financial statements and analysis for the fiscal year. FY 2024
2025-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is titled '감사보고서 제출' (Submission of Audit Report) and provides a summary of the audit opinion, key financial figures, and the auditor's name. While it contains financial data, it is a regulatory filing announcing the submission of the audit report to the exchange, rather than the full annual report or a standalone audit report document. Given the short length and the nature of the announcement, it fits the definition of a regulatory filing regarding the submission of a report. FY 2024
2025-03-11 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Baskhan Bio Pharm. It contains the agenda for the upcoming Annual General Meeting (AGM), including items such as the approval of financial statements, election of directors, and remuneration limits. While it contains financial data (financial statements), this is provided as part of the 'Management Reference' (경영참고사항) required for shareholders to review prior to the meeting. This document is a standard proxy solicitation and information statement for an AGM.
2025-03-11 Korean

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.